Evolve Private Wealth LLC Purchases New Position in Pediatrix Medical Group, Inc. $MD

Evolve Private Wealth LLC acquired a new position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) in the second quarter, HoldingsChannel reports. The institutional investor acquired 35,749 shares of the company’s stock, valued at approximately $906,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Pediatrix Medical Group in the 2nd quarter worth about $347,383,000. Wasatch Advisors LP acquired a new position in shares of Pediatrix Medical Group during the 1st quarter worth approximately $43,861,000. Bank of New York Mellon Corp bought a new position in shares of Pediatrix Medical Group during the second quarter worth approximately $14,297,000. Rockefeller Capital Management L.P. boosted its stake in shares of Pediatrix Medical Group by 814.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 594,351 shares of the company’s stock valued at $12,713,000 after buying an additional 529,367 shares during the period. Finally, Ameriprise Financial Inc. boosted its stake in shares of Pediatrix Medical Group by 175.4% in the second quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock valued at $10,683,000 after buying an additional 474,186 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on MD. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $25.00 target price on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. Jefferies Financial Group downgraded shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating and boosted their price objective for the company from $27.00 to $28.00 in a research report on Wednesday. UBS Group upped their target price on Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Mizuho set a $24.00 target price on Pediatrix Medical Group in a report on Friday, May 8th. Finally, Truist Financial boosted their price target on Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $25.00.

Pediatrix Medical Group Trading Up 0.1%

Shares of Pediatrix Medical Group stock opened at $26.59 on Monday. The firm’s 50 day moving average is $25.77 and its 200 day moving average is $22.98. The firm has a market capitalization of $2.16 billion, a PE ratio of 12.72 and a beta of 0.66. Pediatrix Medical Group, Inc. has a 1 year low of $15.69 and a 1 year high of $27.94. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.45.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The business had revenue of $487.78 million during the quarter, compared to the consensus estimate of $478.49 million. During the same quarter in the prior year, the firm earned $0.53 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. Equities research analysts forecast that Pediatrix Medical Group, Inc. will post 2.17 earnings per share for the current fiscal year.

Pediatrix Medical Group News Summary

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Zacks increased its FY2026 EPS estimate to $2.11 from $2.02 and lifted its Q2 2027 forecast to $0.53 from $0.50. The firm also raised its FY2027 estimate to $2.10 from $1.94 and its FY2028 estimate to $2.04 from $1.88.
• Positive Sentiment: Quarterly estimates were raised for Q1 2027 to $0.37 from $0.34, Q3 2027 to $0.57 from $0.50, Q4 2027 to $0.63 from $0.59, and Q2 2028 to $0.49 from $0.43. These revisions suggest analysts see improving earnings potential beyond the current year.
• Positive Sentiment: Zacks also characterized MD as a strong momentum stock, which may attract additional buying from investors using quantitative or style-based strategies. Here’s Why Pediatrix Medical Group Is a Strong Momentum Stock
• Neutral Sentiment: The current-year consensus EPS forecast remains $2.15, above Zacks’ revised $2.11 estimate for FY2026, indicating that the upgrades have not yet translated into a broader consensus increase.
• Negative Sentiment: Zacks lowered its Q1 2028 EPS forecast to $0.34 from $0.36, a relatively minor negative revision that partly offsets the broader pattern of upward estimate changes.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.